文献速递胸部CT

致命肺癌病例的Lung-RADS v2022回顾性特征分析:NLST研究

Retrospective Lung-RADS v2022 Characterization of Fatal Lung Cancer Cases in the National Lung Screening Trial.
PubMed 文献 · Acad Radiol · 2026-10-16

本研究对NLST低剂量CT筛查臂中91例肺癌死亡病例的筛查CT进行Lung-RADS v2022回顾性评估,发现24%存在回顾可见的可疑结节(漏诊),18%有可见但不符合可疑标准的结节(不可召回),55%无可见结节。漏诊结节常为胸膜旁、被遮挡或不规则边缘;不可召回结节多小于6mm、胸膜旁或不规则边缘。

要点

  • 致命肺癌病例中约四分之一存在回顾可见且符合Lung-RADS v2022可疑标准的结节,提示漏诊可能。
  • 胸膜旁、被遮挡或不规则边缘的结节易被漏诊或归为不可召回。
  • 不可召回结节多小于6mm,需关注小结节随访策略。

关键影像表现/征象

  • 漏诊结节中41%位于胸膜旁,50%被遮挡,68%边缘不规则。
  • 不可召回结节中75%小于6mm,56%位于胸膜旁,56%边缘不规则。

诊断标准与关键数值

  • 91例中22例(24%;95%CI 17%-34%)有回顾可见且符合Lung-RADS v2022可疑标准的结节(漏诊)。
  • 16例(18%;95%CI 11%-27%)有可见但不符合可疑标准的结节(不可召回)。
  • 50例(55%;95%CI 45%-65%)无回顾可见结节,3例(3.3%)结论不确定。

临床应用与阅片要点

  • 阅片时需特别关注胸膜旁、被遮挡或边缘不规则的结节,避免漏诊。
  • 对小于6mm的结节应结合Lung-RADS v2022标准谨慎评估,注意随访。

局限性

  • 本研究为回顾性、结局富集的选择性病例系列,不能代表人群水平Lung-RADS性能。
  • 排除标准较多(如基线筛查阳性、筛查不完整等),可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Persistent lung cancer mortality despite screening is multifactorial. Characterizing computed tomography (CT) findings preceding fatal lung cancer may identify imaging features and screening challenges that warrant further study.

MATERIALS AND METHODS: We conducted a retrospective, outcome-enriched case series nested within the 26,722-participant low-dose computed tomography arm of the National Lung Screening Trial. Among 359 participants who died of lung cancer within the prespecified interval, exclusions for positive baseline screening (n = 186), incomplete screening (n = 28), withdrawal/declined screening (n = 19), unavailable CTs (n = 6), or three negative screens followed by death 2+ years after the final screen (n = 29) yielded 91 participants. Screening CTs were retrospectively assessed using the Lung Imaging Reporting and Data System (Lung-RADS) v2022. Four thoracic radiologists independently reviewed visible-in-retrospect nodules and adjudicated whether they met criteria for suspicion.

RESULTS: Of 91 participants, 22 (24%; 95% confidence interval (CI), 17%-34%) had visible-in-retrospect nodules considered suspicious under Lung-RADS v2022 ("missed"), 16 (18%; 95% CI, 11%-27%) had visible nodules not meeting suspicion criteria ("not callable"), 50 (55%; 95% CI, 45%-65%) had no visible-in-retrospect nodule, and 3 (3.3%) were inconclusive. Missed nodules were frequently juxtapleural (41%), obscured (50%), or irregularly bordered (68%); not-callable nodules were frequently <6 mm (75%), juxtapleural (56%), or irregularly bordered (56%).

CONCLUSION: In this selected fatal-case series, small and juxtapleural nodules were common among visible nodules not meeting Lung-RADS v2022 suspicion criteria. These findings warrant evaluation in representative screening populations and should not be interpreted as estimates of population-level Lung-RADS performance.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Tanwar A, Ebrahimzadeh S, Vella M, et al. Retrospective Lung-RADS v2022 Characterization of Fatal Lung Cancer Cases in the National Lung Screening Trial. Acad Radiol. 2026. PMID: 42888057. doi:10.1016/j.acra.2026.09.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。